Global Orthopedic Oncology Market Snapshot

According to Future Market Insights research, during the projected period, the global orthopedic oncology market is expected to grow at a CAGR of 6.5%. The market value is projected to increase from US$  1.2 Billion in 2023 to US$ 2.3 Billion by 2033. The orthopedic oncology market was valued at US$ 1.1 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 7.2% in 2023.

Market Outlook:

Data Points Market Insights
Market Value 2022 US$ 1.1  Billion
Market Value 2023 US$ 1.2 Billion
Market Value 2033 US$ 2.3 Billion
CAGR 2023 to 2033 6.5%
Market Share of Top 5 Countries 54.1%
Key Market Players General Electric (GE) Healthcare, Siemens Healthineers, Koninklijke Philips N.V., Hitachi Medical Systems, Hologic, Shimadzu Medical Systems, Carestream Health, Canon Medical Systems, FUJIFILM Medical Systems, Ziehm Imaging, Planmed Oy, EOS imaging, Medtronic plc, Stryker Corporation, Cook Medical, Zimmer Biomet, Biopsybell, Becton Dickenson & Company, and Teleflex Inc.

Orthopedic oncology is a specialized field of medicine which focuses on diagnosing and treatment of bone and soft tissue tumors, both benign and malignant, within the musculoskeletal system. The orthopedic oncology market is driven by multiple factors such as increasing incidences of bone and soft tissue tumours, and advancements in diagnostic techniques and treatment modalities. The field involves orthopedic surgeons, radiologists, and pathologists to give comprehensive care to patients with bone and soft tissue cancer.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of Orthopedic Oncology Market from 2017 to 2022 Vs Market Outlook for 2023 to 2033

The market value for orthopedic oncology was around 0.6% of the overall US$ 191.3 Billion of the global cancer diagnostics market in 2022. The diagnostics of orthopedic oncology expanded at a CAGR of 6.3% from 2017–2022, due to the increasing cases of musculoskeletal cancer.

Orthopedic oncology emerged as a distinct field in the late 1960s and early 1970s when orthopedic surgeons recognized the need for specialized care for patients with bone and soft tissue tumors. The development of advanced imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scans greatly improved the ability to diagnose and stage tumors accurately, enabling better treatment planning.

Several macroeconomic factors have been affecting the market among which healthcare spending has had a crucial impact on the market.

According to the journal Inquiry 2019, healthcare spending on treatment for cancer has also risen dramatically during the last two decades. Cancer research has resulted in advancements in the early detection and management of cancer during the last several decades, leading to decreases in overall mortality and incidence attributable to cancer.

According to data from the Agency for Healthcare Research and Quality, $57 billion was invested in treatment for cancer in 2001, rising to $88.3 billion in 2011,8 and the National Cancer Institute predicted that national projections of cancer care expenses might reach $173 billion by 2020.

What are the Key Opportunities for the Orthopedic Oncology Manufacturers?

Musculoskeletal tumours represent an uncommon and diverse group of tumours. Sarcomas of the bone and cartilage account for less than one per cent of all cancers in humans. Their prevalence is much higher in youngsters than in adults. The market is affected by the availability of innovative treatment options including targeted therapies and immunotherapies. The number of cancer patients globally is increasing, and technological developments such as image reconstruction programmes, imaging equipment, biomarkers, as well as artificial intelligence algorithms are helping in imaging techniques and surgical techniques are influencing the orthopedic oncology industry.

Techniques such as magnetic resonance imaging (MRI) and computed tomography (CT) scan aid in tumour diagnosis and assessment, while limb-salvage surgeries and reconstructive procedures have improved patients' health. The orthopedic oncology market is likely to expand in the future years, owing to factors such as the rising prevalence of bone and soft tissue tumours, technological developments, and the development of novel treatment options.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand for the Orthopedic Oncology?

High treatment expenses, including surgeries, radiation therapy, and chemotherapy, are one of the factors that could limit the growth of the orthopedic oncology market. Patients face financial constraints as a result, limiting their access to effective care, particularly in underdeveloped nations. Another issue will be the scarcity of clinical data and research possibilities. The lack of cutting-edge medicines for patients and poor progress in cancer research impede the development of new treatment choices and creative remedies.

Country-wise Insights

Why is the USA a Prominent Market for Orthopedic Oncology in North America region?

The USA occupies 26.2% share in global market in 2022.

According to the American Cancer Society 2021, Americans are at risk of chondrosarcoma for a variety of causes, including advanced age, enchondroma or multiple enchondromatosis, which is connected to mutations in the IDH1 or IDH2 genes. People who have received radiation therapy (typically to treat another type of cancer) have an increased risk of acquiring bone cancer, according to the Centre for Disease Control and Prevention 2020.

These factors make the USA population more favourable to the orthopedic oncology market. Along with this USA has a well-developed healthcare system with advanced medical infrastructure for the diagnosis and treatment of tumor, thus making the USA a prominent market for orthopedic oncology.

What Makes China a Highly Lucrative Market for Orthopedic Oncology?

China’s revenue generation on orthopedic oncology diagnosis in 2022 was US$ 105.0 Million.

According to Medical Express 2022, In the year 2022, China would have 4.82 million new instances of cancer and 3.21 million deaths due to cancer. The basic occurrence rate for primary bone malignancies was 1.76/100,000 Chinese standard population (ASIRC) as per Clinical Cases in Mineral and Bone Metabolism data from 2012.

China has a strong emphasis on research and development in the field of cancer treatment. As per an article in The Lancet Oncology 2021, The country invests significantly in medical research and clinical trials, and the development of innovative therapies. This focus on research and innovation attracts leading experts and encourages collaboration between the healthcare and pharmaceutical industries. Thus making China a highly lucrative market for orthopedic oncology.

What Makes India a Large Market for Orthopedic Oncology?

In 2022, India held a dominant share of the East Asia market and contributed around US$ 87.9 Million.

The country's rapidly growing economic condition of the middle-class population has increased spending on healthcare and discretionary income. India has a well-developed healthcare system with excellent medical facilities, research institutions, and specialised cancer hospitals.

Recently, in January 2022, Ayushman Bharat approved bone marrow transplants, which are frequently advised to cancer patients. With a population of 1.4 billion, India has a high probability of orthopedic oncology cases. The healthcare scheme is a strength for the population with low socioeconomic backgrounds; as the government of India bears the maximum cost, more and more patients will opt for treatment, resulting in the growth of the orthopedic oncology market in India.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Why Diagnostics Imaging is Preferred Majorly in Orthopedic Oncology Market?

The market value of diagnostics imaging used for diagnosis is US$ 715.1 Million, representing a sizable 62.3% global market share in 2022. Recently, the Musculoskeletal Tumour Society and the American Academy of Orthopedic Surgeons 2018, agreed upon a clinical practice suggestion titled Use of Imaging before Referral to an orthopedic oncologist.

In the absence of credible data, conventional radiographs are a reasonable diagnostic tool that should be explored during the first evaluation of a soft-tissue tumour. Diagnostics imaging is recommended in orthopedic oncology because it provides precise anatomical details, aids in staging and treatment planning, monitors therapy response and reduces invasiveness and patient pain.

Which Stage of Cancer Will Garner Significant Value Share by 2023?

Stage I of cancer contributes to 36.9% market share in 2022 and is expected to grow with a CAGR of 8.0%. In general, the initial stage of cancer is curable and has a higher possibility of success than the subsequent phases. As a result of the increased emphasis on detection and diagnosis, a greater percentage of patients are recognised and treated in stage I.

Medical technological advancements and growing awareness of the need for early diagnosis have resulted in enhanced screening procedures and increased involvement in cancer screening programmes.

Which Disease Indication is the Most Frequent in Orthopedic Oncology Market?

By indications, osteosarcoma accounted for a predominant share of the global market, with a revenue share of 45.6% in 2022.

According to an article published in Société Internationale de Chirurgie Orthopédique et de Traumatologie 2018, Osteosarcoma (OS) is a type of main malignant bones tumour that affects 3.4 per million individuals globally each year. With an annual incidence of 5.6 cases per million adolescents below the age of 15, OS is the third most frequent cancer during adolescence, after only lymphomas and brain tumours. The greatest prevalence occurs during the second decade of adulthood.

Osteosarcoma was once assumed to be a radioresistant malignancy. However, advances in radiotherapy that makes it possible for the secure delivery of high doses of radiation are encouraging for patients with inoperable or insufficiently resected axial bones. It is aggressive and grows quickly, with an elevated risk and chance of spreading to other regions of the body; hence, it is prevalent in orthopedic oncology.

Which End User is Benefiting the Global Market?

The hospitals have a considerable presence in the orthopedic oncology market, accounting for 48.9% of end users and exhibiting a prominent Compound Annual Growth Rate (CAGR) of 6.0%.

Hospitals are well-equipped with types of equipment and instruments for the diagnosis and treatment of orthopedic cancer. The doctors, nurses and other staff are readily available for treatment and care, and the patient with special care can be admitted to hospital wards. The physicians can observe and treat patients 24*7 in the hospital. Hence these factors make hospitals major benefitting end users in the market.

Competitive Landscape

Collaborations and partnerships among hospitals, healthcare providers, research institutions, and technology businesses can encourage innovation and hasten orthopedic oncology diagnosis and treatment. Many pharmaceutical industries are involved in Research and Development and the development of drugs for the treatment of orthopedic cancer. Among the well-known players in this field are:

Deep learning is being used by the AI-powered platform to boost automation and make MRI scanning more efficient for hospitals dealing with concerns such as staff burnout and rising electricity expenditures.

  • In November 2022, GE Healthcare launched Ai driven SIGNA Experience platform. With this new technology detection and diagnosis with high accuracy become easy in hospitals.

The research institutions and medical schools have formed an innovative collaboration to advance personalised medicine and provide consumers with high-quality, cost-effective healthcare.

  • In July 2022, Siemens Healthineers Announces Strategic Partnership with The Ohio State University Wexner Medical Center. The research insights will be shared by the university and with large sponsorship and funding from Siemens Healthineers.

Similarly, recent developments related to the company’s active within the orthopedic oncology market space have been tracked by the team at Future Market Insights, which are available in the full report.

Report Scope as Per Orthopedic Oncology Industry Analysis

Attribute Details
Forecast Period 2023 to 2033
Historical Data Available for 2017 to 2022
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA)
Key Countries Covered USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, India, Thailand, China, Indonesia, Malaysia, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye Northern Africa and South Africa.
Key Market Segments Covered Diagnostic Techniques, Cancer Stage, Indications, End User, and Region
Key Companies Profiled
  • General Electric (GE) Healthcare
  • Siemens Healthineers
  • Koninklijke Philips N.V.
  • Hitachi Medical Systems
  • Hologic
  • Shimadzu Medical Systems
  • Carestream Health
  • Canon Medical Systems
  • FUJIFILM Medical Systems
  • Ziehm Imaging
  • Planmed Oy
  • EOS imaging
  • Medtronic plc
  • Stryker Corporation
  • Cook Medical
  • Zimmer Biomet
  • Biopsybell
  • Becton Dickenson & Company
  • Teleflex Inc.
Report Coverage
  • Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing Available upon Request

Key Market Segments Covered in the Orthopedic Oncology Industry Research

By Diagnostic Techniques:

  • Diagnostic Imaging
    • X-ray Imaging
    • MRI Imaging
    • CT Imaging
    • PET Imaging
    • Ultrasound Imaging
  • Bone Biopsy
    • Biopsy Needles
    • Biospy Trays & Kits

By Cancer Stage:

  • Stage I
  • Stage II
  • Stage III
  • Stage IV

By Indication:

  • Osteosarcoma
  • Chondrosarcoma
  • Ewing Sarcoma
  • Chordroma

By End User:

  • Hospitals
  • Diagnostic Centres
  • Specialty Orthopedic Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

What is the market value in 2023?

In 2023, the market is valued US$ 1.2 billion.

What will be the growth rate until 2033?

Until 2033, the market will experience a 6.5% CAGR.

What is majorly propelling the market growth?

Growing prevalence of bone and soft tissue tumors drives market growth.

What is the CAGR for Stage I?

Stage I will expand at an 8.0% CAGR through 2033.

Who are some key market players?

General Electric (GE) Healthcare, Siemens Healthineers, and Koninklijke Philips N.V. are some key players.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply-Side Trends

    1.4. Technology Roadmap

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Innovation / Development Trends

4. Value-Added Insights

    4.1. Disease Epidemiology

    4.2. Diagnostic Techniques Adoption/Usage Analysis

    4.3. Regulatory Landscape, By Country

    4.4. Reimbursement Scenario

    4.5. Procedure Based Scenarios

    4.6. Porter’s Analysis

    4.7. PESTLE Analysis

    4.8. Value Chain Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global Healthcare Expenditure Outlook

        5.1.2. Global Oncology Market Outlook (Parent Market)

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Rising Need for Diagnostic Technique

        5.2.2. Increasing Prevalence of Cancer Cases

        5.2.3. Growth of Clinical Diagnostics

        5.2.4. Technological Advancements in Imaging

        5.2.5. New Initiatives For Diagnostic Techniques Development

        5.2.6. Cost of Diagnostic Equipment’s

        5.2.7. Cost of the Treatment

        5.2.8. Research and Development in Cancer Diagnostics

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033

    6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022

    6.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033

        6.2.1. Y-o-Y Growth Trend Analysis

        6.2.2. Absolute $ Opportunity Analysis

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Diagnostic Techniques

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Million) Analysis By Diagnostic Techniques, 2017 to 2022

    7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Diagnostic Techniques, 2023 to 2033

        7.3.1. Diagnostic Imaging

            7.3.1.1. X-ray Imaging

            7.3.1.2. MRI Imaging

            7.3.1.3. CT Imaging

            7.3.1.4. PET Imaging

            7.3.1.5. Ultrasound Imaging

        7.3.2. Bone Biopsy

            7.3.2.1. Biopsy Needles

            7.3.2.2. Biopsy Trays & Kits

    7.4. Market Attractiveness Analysis By Diagnostic Techniques

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Cancer Stage

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Million) Analysis By Cancer Stage, 2017 to 2022

    8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Cancer Stage, 2023 to 2033

        8.3.1. Stage I

        8.3.2. Stage II

        8.3.3. Stage III

        8.3.4. Stage IV

    8.4. Market Attractiveness Analysis By Cancer Stage

9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022

    9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033

        9.3.1. Osteosarcoma

        9.3.2. Chondrosarcoma

        9.3.3. Ewing Sarcoma

        9.3.4. Chordroma

    9.4. Market Attractiveness Analysis By Indication

10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Million) Analysis By End User, 2017 to 2022

    10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        10.3.1. Hospitals

        10.3.2. Diagnostic Centres

        10.3.3. Specialty Orthopedic Clinics

    10.4. Market Attractiveness Analysis By End User

11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022

    11.3. Current and Future Market Size (US$ Million) and Forecast By Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. South Asia

        11.3.5. East Asia

        11.3.6. Oceania

        11.3.7. Middle East and Africa

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        12.3.1. By Country

            12.3.1.1. USA

            12.3.1.2. Canada

        12.3.2. By Diagnostic Techniques

        12.3.3. By Cancer Stage

        12.3.4. By Indication

        12.3.5. By End User

    12.4. Market Attractiveness Analysis By Region

        12.4.1. By Country

        12.4.2. By Diagnostic Techniques

        12.4.3. By Cancer Stage

        12.4.4. By Indication

        12.4.5. By End User

    12.5. Market trends

    12.6. Key Market Participants - Intensity Mapping

    12.7. Drivers and Restraints - Impact Analysis

    12.8. Country Level Analysis & Forecast

        12.8.1. USA Market Analysis

            12.8.1.1. Introduction

            12.8.1.2. Market Analysis and Forecast by Market Taxonomy

                12.8.1.2.1. By Diagnostic Techniques

                12.8.1.2.2. By Cancer Stage

                12.8.1.2.3. By Indication

                12.8.1.2.4. By End User

        12.8.2. Canada Market Analysis

            12.8.2.1. Introduction

            12.8.2.2. Market Analysis and Forecast by Market Taxonomy

                12.8.2.2.1. By Diagnostic Techniques

                12.8.2.2.2. By Cancer Stage

                12.8.2.2.3. By Indication

                12.8.2.2.4. By End User

13. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    13.1. Introduction / Key Findings

    13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        13.3.1. By Country

            13.3.1.1. Brazil

            13.3.1.2. Mexico

            13.3.1.3. Argentina

            13.3.1.4. Rest of Latin America

        13.3.2. By Diagnostic Techniques

        13.3.3. By Cancer Stage

        13.3.4. By Indication

        13.3.5. By End User

    13.4. Market Attractiveness Analysis By Region

        13.4.1. By Country

        13.4.2. By Diagnostic Techniques

        13.4.3. By Cancer Stage

        13.4.4. By Indication

        13.4.5. By End User

    13.5. Market trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. Brazil Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast by Market Taxonomy

                13.8.1.2.1. By Diagnostic Techniques

                13.8.1.2.2. By Cancer Stage

                13.8.1.2.3. By Indication

                13.8.1.2.4. By End User

        13.8.2. Mexico Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast by Market Taxonomy

                13.8.2.2.1. By Diagnostic Techniques

                13.8.2.2.2. By Cancer Stage

                13.8.2.2.3. By Indication

                13.8.2.2.4. By End User

        13.8.3. Argentina Market Analysis

            13.8.3.1. Introduction

            13.8.3.2. Market Analysis and Forecast by Market Taxonomy

                13.8.3.2.1. By Diagnostic Techniques

                13.8.3.2.2. By Cancer Stage

                13.8.3.2.3. By Indication

                13.8.3.2.4. Type By End User

14. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    14.1. Introduction / Key Findings

    14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        14.3.1. By Country

            14.3.1.1. Germany

            14.3.1.2. France

            14.3.1.3. Spain

            14.3.1.4. Russia

            14.3.1.5. Italy

            14.3.1.6. BENELUX

            14.3.1.7. Nordics

            14.3.1.8. United Kingdom

            14.3.1.9. Rest of Europe

        14.3.2. By Diagnostic Techniques

        14.3.3. By Cancer Stage

        14.3.4. By Indication

        14.3.5. By End User

    14.4. Market Attractiveness Analysis By Region

        14.4.1. By Country

        14.4.2. By Diagnostic Techniques

        14.4.3. By Cancer Stage

        14.4.4. By Indication

        14.4.5. By End User

    14.5. Market trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Germany Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast by Market Taxonomy

                14.8.1.2.1. By Diagnostic Techniques

                14.8.1.2.2. By Cancer Stage

                14.8.1.2.3. By Indication

                14.8.1.2.4. By End User

        14.8.2. France Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast by Market Taxonomy

                14.8.2.2.1. By Diagnostic Techniques

                14.8.2.2.2. By Cancer Stage

                14.8.2.2.3. By Indication

                14.8.2.2.4. By End User

        14.8.3. Spain Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast by Market Taxonomy

                14.8.3.2.1. By Diagnostic Techniques

                14.8.3.2.2. By Cancer Stage

                14.8.3.2.3. By Indication

                14.8.3.2.4. Type By End User

        14.8.4. Russia Market Analysis

            14.8.4.1. Introduction

            14.8.4.2. Market Analysis and Forecast by Market Taxonomy

                14.8.4.2.1. By Diagnostic Techniques

                14.8.4.2.2. By Cancer Stage

                14.8.4.2.3. By Indication

                14.8.4.2.4. Type By End User

        14.8.5. Italy Market Analysis

            14.8.5.1. Introduction

            14.8.5.2. Market Analysis and Forecast by Market Taxonomy

                14.8.5.2.1. By Diagnostic Techniques

                14.8.5.2.2. By Cancer Stage

                14.8.5.2.3. By Indication

                14.8.5.2.4. By End User

        14.8.6. BENELUX Market Analysis

            14.8.6.1. Introduction

            14.8.6.2. Market Analysis and Forecast by Market Taxonomy

                14.8.6.2.1. By Diagnostic Techniques

                14.8.6.2.2. By Cancer Stage

                14.8.6.2.3. By Indication

                14.8.6.2.4. By End User

        14.8.7. Nordics Market Analysis

            14.8.7.1. Introduction

            14.8.7.2. Market Analysis and Forecast by Market Taxonomy

                14.8.7.2.1. By Diagnostic Techniques

                14.8.7.2.2. By Cancer Stage

                14.8.7.2.3. By Indication

                14.8.7.2.4. By End User

        14.8.8. United Kingdom Market Analysis

            14.8.8.1. Introduction

            14.8.8.2. Market Analysis and Forecast by Market Taxonomy

                14.8.8.2.1. By Diagnostic Techniques

                14.8.8.2.2. By Cancer Stage

                14.8.8.2.3. By Indication

                14.8.8.2.4. By End User

15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    15.1. Introduction / Key Findings

    15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        15.3.1. By Country

            15.3.1.1. India

            15.3.1.2. Indonesia

            15.3.1.3. Thailand

            15.3.1.4. Philippines

            15.3.1.5. Malaysia

            15.3.1.6. Vietnam

            15.3.1.7. Rest of South Asia

        15.3.2. By Diagnostic Techniques

        15.3.3. By Cancer Stage

        15.3.4. By Indication

        15.3.5. By End User

    15.4. Market Attractiveness Analysis By Region

        15.4.1. By Country

        15.4.2. By Diagnostic Techniques

        15.4.3. By Cancer Stage

        15.4.4. By Indication

        15.4.5. By End User

    15.5. Market trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. India Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast by Market Taxonomy

                15.8.1.2.1. By Diagnostic Techniques

                15.8.1.2.2. By Cancer Stage

                15.8.1.2.3. By Indication

                15.8.1.2.4. By End User

        15.8.2. Indonesia Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast by Market Taxonomy

                15.8.2.2.1. By Diagnostic Techniques

                15.8.2.2.2. By Cancer Stage

                15.8.2.2.3. By Indication

                15.8.2.2.4. By End User

        15.8.3. Thailand Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast by Market Taxonomy

                15.8.3.2.1. By Diagnostic Techniques

                15.8.3.2.2. By Cancer Stage

                15.8.3.2.3. By Indication

                15.8.3.2.4. By End User

        15.8.4. Philippines Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast by Market Taxonomy

                15.8.4.2.1. By Diagnostic Techniques

                15.8.4.2.2. By Cancer Stage

                15.8.4.2.3. By Indication

                15.8.4.2.4. By End User

        15.8.5. Malaysia Market Analysis

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast by Market Taxonomy

                15.8.5.2.1. By Diagnostic Techniques

                15.8.5.2.2. By Cancer Stage

                15.8.5.2.3. By Indication

                15.8.5.2.4. By End User

        15.8.6. Vietnam Market Analysis

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast by Market Taxonomy

                15.8.6.2.1. By Diagnostic Techniques

                15.8.6.2.2. By Cancer Stage

                15.8.6.2.3. By Indication

                15.8.6.2.4. By End User

16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    16.1. Introduction / Key Findings

    16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Diagnostic Techniques

        16.3.3. By Cancer Stage

        16.3.4. By Indication

        16.3.5. By End User

    16.4. Market Attractiveness Analysis By Region

        16.4.1. By Country

        16.4.2. By Diagnostic Techniques

        16.4.3. By Cancer Stage

        16.4.4. By Indication

        16.4.5. By End User

    16.5. Market trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. China Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast by Market Taxonomy

                16.8.1.2.1. By Diagnostic Techniques

                16.8.1.2.2. By Cancer Stage

                16.8.1.2.3. By Indication

                16.8.1.2.4. By End User

        16.8.2. Japan Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast by Market Taxonomy

                16.8.2.2.1. By Diagnostic Techniques

                16.8.2.2.2. By Cancer Stage

                16.8.2.2.3. By Indication

                16.8.2.2.4. By End User

        16.8.3. South Korea Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast by Market Taxonomy

                16.8.3.2.1. By Diagnostic Techniques

                16.8.3.2.2. By Cancer Stage

                16.8.3.2.3. By Indication

                16.8.3.2.4. By End User

17. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    17.1. Introduction / Key Findings

    17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        17.3.1. By Country

            17.3.1.1. Australia

            17.3.1.2. New Zealand

        17.3.2. By Diagnostic Techniques

        17.3.3. By Cancer Stage

        17.3.4. By Indication

        17.3.5. By End User

    17.4. Market Attractiveness Analysis By Region

        17.4.1. By Country

        17.4.2. By Diagnostic Techniques

        17.4.3. By Cancer Stage

        17.4.4. By Indication

        17.4.5. By End User

    17.5. Market trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. Australia Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast by Market Taxonomy

                17.8.1.2.1. By Diagnostic Techniques

                17.8.1.2.2. By Cancer Stage

                17.8.1.2.3. By Indication

                17.8.1.2.4. By End User

        17.8.2. New Zealand Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast by Market Taxonomy

                17.8.2.2.1. By Diagnostic Techniques

                17.8.2.2.2. By Cancer Stage

                17.8.2.2.3. By Indication

                17.8.2.2.4. By End User

18. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033

    18.1. Introduction / Key Findings

    18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2017 to 2022

    18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033

        18.3.1. By Country

            18.3.1.1. GCC Countries

            18.3.1.2. Türkiye

            18.3.1.3. South Africa

            18.3.1.4. Northern Africa

            18.3.1.5. Rest of Middle East and Africa

        18.3.2. By Diagnostic Techniques

        18.3.3. By Cancer Stage

        18.3.4. By Indication

        18.3.5. By End User

    18.4. Market Attractiveness Analysis By Region

        18.4.1. By Country

        18.4.2. By Diagnostic Techniques

        18.4.3. By Cancer Stage

        18.4.4. By Indication

        18.4.5. By End User

    18.5. Market trends

    18.6. Key Market Participants - Intensity Mapping

    18.7. Drivers and Restraints - Impact Analysis

    18.8. Country Level Analysis & Forecast

        18.8.1. GCC Countries Market Analysis

            18.8.1.1. Introduction

            18.8.1.2. Market Analysis and Forecast by Market Taxonomy

                18.8.1.2.1. By Diagnostic Techniques

                18.8.1.2.2. By Cancer Stage

                18.8.1.2.3. By Indication

                18.8.1.2.4. By End User

        18.8.2. Türkiye Market Analysis

            18.8.2.1. Introduction

            18.8.2.2. Market Analysis and Forecast by Market Taxonomy

                18.8.2.2.1. By Diagnostic Techniques

                18.8.2.2.2. By Cancer Stage

                18.8.2.2.3. By Indication

                18.8.2.2.4. By End User

        18.8.3. South Africa Market Analysis

            18.8.3.1. Introduction

            18.8.3.2. Market Analysis and Forecast by Market Taxonomy

                18.8.3.2.1. By Diagnostic Techniques

                18.8.3.2.2. By Cancer Stage

                18.8.3.2.3. By Indication

                18.8.3.2.4. By End User

        18.8.4. Northern Africa Market Analysis

            18.8.4.1. Introduction

            18.8.4.2. Market Analysis and Forecast by Market Taxonomy

                18.8.4.2.1. By Diagnostic Techniques

                18.8.4.2.2. By Cancer Stage

                18.8.4.2.3. By Indication

                18.8.4.2.4. By End User

19. Market Structure Analysis

    19.1. Market Analysis by Tier of Companies

    19.2. Market Share Analysis of Top Players (%)

    19.3. Market Presence Analysis

        19.3.1. Regional Footprint of Players

        19.3.2. Product Footprint of Players

        19.3.3. Channel Footprint of Players

20. Competition Analysis

    20.1. Competition Dashboard

    20.2. Key Development Analysis

    20.3. branding and Promotional Strategies, By Key Players

    20.4. Competition Deep Dive

        20.4.1. General Electric (GE) Healthcare.

            20.4.1.1. Overview

            20.4.1.2. Product Portfolio

            20.4.1.3. Key Financials

            20.4.1.4. Sales Footprint

            20.4.1.5. Strategy Overview

                20.4.1.5.1. Marketing Strategies

                20.4.1.5.2. Channel Strategies

                20.4.1.5.3. Product Strategies

        20.4.2. Siemens Healthineers

            20.4.2.1. Overview

            20.4.2.2. Product Portfolio

            20.4.2.3. Key Financials

            20.4.2.4. Sales Footprint

            20.4.2.5. Strategy Overview

                20.4.2.5.1. Marketing Strategies

                20.4.2.5.2. Channel Strategies

                20.4.2.5.3. Product Strategies

        20.4.3. Koninklijke Philips N.V.

            20.4.3.1. Overview

            20.4.3.2. Product Portfolio

            20.4.3.3. Key Financials

            20.4.3.4. Sales Footprint

            20.4.3.5. Strategy Overview

                20.4.3.5.1. Marketing Strategies

                20.4.3.5.2. Channel Strategies

                20.4.3.5.3. Product Strategies

        20.4.4. Hitachi Medical Systems

            20.4.4.1. Overview

            20.4.4.2. Product Portfolio

            20.4.4.3. Key Financials

            20.4.4.4. Sales Footprint

            20.4.4.5. Strategy Overview

                20.4.4.5.1. Marketing Strategies

                20.4.4.5.2. Channel Strategies

                20.4.4.5.3. Product Strategies

        20.4.5. Hologic

            20.4.5.1. Overview

            20.4.5.2. Product Portfolio

            20.4.5.3. Key Financials

            20.4.5.4. Sales Footprint

            20.4.5.5. Strategy Overview

                20.4.5.5.1. Marketing Strategies

                20.4.5.5.2. Channel Strategies

                20.4.5.5.3. Product Strategies

        20.4.6. Shimadzu Medical Systems

            20.4.6.1. Overview

            20.4.6.2. Product Portfolio

            20.4.6.3. Key Financials

            20.4.6.4. Sales Footprint

            20.4.6.5. Strategy Overview

                20.4.6.5.1. Marketing Strategies

                20.4.6.5.2. Channel Strategies

                20.4.6.5.3. Product Strategies

        20.4.7. Carestream Health

            20.4.7.1. Overview

            20.4.7.2. Product Portfolio

            20.4.7.3. Key Financials

            20.4.7.4. Sales Footprint

            20.4.7.5. Strategy Overview

                20.4.7.5.1. Marketing Strategies

                20.4.7.5.2. Channel Strategies

                20.4.7.5.3. Product Strategies

        20.4.8. Canon Medical Systems

            20.4.8.1. Overview

            20.4.8.2. Product Portfolio

            20.4.8.3. Key Financials

            20.4.8.4. Sales Footprint

            20.4.8.5. Strategy Overview

                20.4.8.5.1. Marketing Strategies

                20.4.8.5.2. Channel Strategies

                20.4.8.5.3. Product Strategies

        20.4.9. FUJIFILM Medical Systems

            20.4.9.1. Overview

            20.4.9.2. Product Portfolio

            20.4.9.3. Key Financials

            20.4.9.4. Sales Footprint

            20.4.9.5. Strategy Overview

                20.4.9.5.1. Marketing Strategies

                20.4.9.5.2. Channel Strategies

                20.4.9.5.3. Product Strategies

        20.4.10. Ziehm Imaging

            20.4.10.1. Overview

            20.4.10.2. Product Portfolio

            20.4.10.3. Key Financials

            20.4.10.4. Sales Footprint

            20.4.10.5. Strategy Overview

                20.4.10.5.1. Marketing Strategies

                20.4.10.5.2. Channel Strategies

                20.4.10.5.3. Product Strategies

        20.4.11. Planmed Oy

            20.4.11.1. Overview

            20.4.11.2. Product Portfolio

            20.4.11.3. Key Financials

            20.4.11.4. Sales Footprint

            20.4.11.5. Strategy Overview

                20.4.11.5.1. Marketing Strategies

                20.4.11.5.2. Channel Strategies

                20.4.11.5.3. Product Strategies

        20.4.12. EOS imaging

            20.4.12.1. Overview

            20.4.12.2. Product Portfolio

            20.4.12.3. Key Financials

            20.4.12.4. Sales Footprint

            20.4.12.5. Strategy Overview

                20.4.12.5.1. Marketing Strategies

                20.4.12.5.2. Channel Strategies

                20.4.12.5.3. Product Strategies

        20.4.13. Medtronic plc

            20.4.13.1. Overview

            20.4.13.2. Product Portfolio

            20.4.13.3. Key Financials

            20.4.13.4. Sales Footprint

            20.4.13.5. Strategy Overview

                20.4.13.5.1. Marketing Strategies

                20.4.13.5.2. Channel Strategies

                20.4.13.5.3. Product Strategies

        20.4.14. Stryker Corporation

            20.4.14.1. Overview

            20.4.14.2. Product Portfolio

            20.4.14.3. Key Financials

            20.4.14.4. Sales Footprint

            20.4.14.5. Strategy Overview

                20.4.14.5.1. Marketing Strategies

                20.4.14.5.2. Channel Strategies

                20.4.14.5.3. Product Strategies

        20.4.15. Cook Medical

            20.4.15.1. Overview

            20.4.15.2. Product Portfolio

            20.4.15.3. Key Financials

            20.4.15.4. Sales Footprint

            20.4.15.5. Strategy Overview

                20.4.15.5.1. Marketing Strategies

                20.4.15.5.2. Channel Strategies

                20.4.15.5.3. Product Strategies

        20.4.16. Zimmer Biomet

            20.4.16.1. Overview

            20.4.16.2. Product Portfolio

            20.4.16.3. Key Financials

            20.4.16.4. Sales Footprint

            20.4.16.5. Strategy Overview

                20.4.16.5.1. Marketing Strategies

                20.4.16.5.2. Channel Strategies

                20.4.16.5.3. Product Strategies

        20.4.17. Biopsybell

            20.4.17.1. Overview

            20.4.17.2. Product Portfolio

            20.4.17.3. Key Financials

            20.4.17.4. Sales Footprint

            20.4.17.5. Strategy Overview

                20.4.17.5.1. Marketing Strategies

                20.4.17.5.2. Channel Strategies

                20.4.17.5.3. Product Strategies

        20.4.18. Becton Dickenson & Company

            20.4.18.1. Overview

            20.4.18.2. Product Portfolio

            20.4.18.3. Key Financials

            20.4.18.4. Sales Footprint

            20.4.18.5. Strategy Overview

                20.4.18.5.1. Marketing Strategies

                20.4.18.5.2. Channel Strategies

                20.4.18.5.3. Product Strategies

        20.4.19. Teleflex Inc.

            20.4.19.1. Overview

            20.4.19.2. Product Portfolio

            20.4.19.3. Key Financials

            20.4.19.4. Sales Footprint

            20.4.19.5. Strategy Overview

                20.4.19.5.1. Marketing Strategies

                20.4.19.5.2. Channel Strategies

                20.4.19.5.3. Product Strategies

21. Assumptions and Acronyms Used

22. Research Methodology

Recommendations

Healthcare

Cancer Tissue Diagnostic Market

March 2021

REP-GB-4191

April 2024

556 pages

Healthcare

Cancer Diagnostics Market

March 2021

REP-GB-1090

August 2023

315 pages

Healthcare

Diagnostic X-Ray System Market

February 2022

REP-GB-667

October 2022

370 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Orthopedic Oncology Market